Sonoma Pharmaceuticals, Inc. - Common Stock (SNOA)
4.2300
+0.3700 (9.59%)
NASDAQ · Last Trade: Apr 27th, 2:55 PM EDT
Detailed Quote
Previous Close
3.860
Open
3.810
Bid
3.900
Ask
4.120
Day's Range
3.650 - 4.300
52 Week Range
1.750 - 9.374
Volume
1,185,932
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,346,387
Chart
About Sonoma Pharmaceuticals, Inc. - Common Stock (SNOA)
Sonoma Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of solutions for dermatology and wound care. The company specializes in creating novel, prescriptive and over-the-counter formulations that utilize its patented technology to produce therapeutic products aimed at treating various skin conditions, infections, and wounds. By leveraging advanced science and research, Sonoma Pharmaceuticals aims to enhance patient outcomes and improve the quality of care in the healthcare sector, prioritizing safety and efficacy in its product offerings. Read More
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
U.S. stock futures continued rising on Wednesday after a day of strong recovery on Tuesday. Futures of major benchmark indices were higher in premarket.
BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom.
Sonoma stock is trading higher on Tuesday after the company announced that it secured U.K. regulatory clearance for its key wound care and dermatology products.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.
BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, March 7-11, 2025.
BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has successfully completed transition to the new European Union (EU) Medical Device Regulation (MDR) for four of its products in Europe.
